<div id="readability-page-1"><p>In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Corvus Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$33.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Jones is a 5-star analyst with an average return of <span>20.6%</span> and a 43.35% success rate. Jones covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Whitehawk Therapeutics, and Alumis Inc..</p> <p>In a report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.</p></div>

CRVS

<p>Oppenheimer's Jeff Jones has reiterated a Buy rating on Corvus Pharmaceuticals (CRVS) with a price target of $33.00. Jones, a 5-star analyst, has an average return of 20.6% and a 43.35% success rate. Barclays also maintains a Buy rating with a $28.00 price target.</p>

Tip Ranks

Corvus Pharma

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VG Health

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

Oppenheimer

Whitehawk Therapeutics

Alumis

Barclays

Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer